PT  - JOURNAL ARTICLE
AU  - ONDREJ VENCLICEK
AU  - JANA SKRICKOVA
AU  - KRISTIAN BRAT
AU  - ONDREJ FISCHER
AU  - LIBOR HAVEL
AU  - MICHAL HRNCIARIK
AU  - MILOSLAV MAREL
AU  - PETR OPALKA
AU  - GABRIELA KRAKOROVA
AU  - DENISA ROZSIVALOVA
AU  - JURAJ KULTAN
AU  - ANDREA MULLEROVA
AU  - LYDIA ZARNAYOVA
AU  - PETRA SMICKOVA
AU  - MARTINA VASAKOVA
AU  - ZSUZSANNA GYORFY
AU  - MICHAL JIROUSEK
AU  - DANIEL KREJCI
AU  - JANA KREJCI
AU  - PETR ZUNA
AU  - MARTIN SVATON
AU  - KRISTYNA HRDA
AU  - JAROSLAV DUBA
AU  - JANA ALAHAKOON
AU  - MICHAL SVOBODA
AU  - JIRI SILAR
TI  - Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry
AID  - 10.21873/anticanres.15368
DP  - 2021 Nov 01
TA  - Anticancer Research
PG  - 5549--5556
VI  - 41
IP  - 11
4099  - http://ar.iiarjournals.org/content/41/11/5549.short
4100  - http://ar.iiarjournals.org/content/41/11/5549.full
SO  - Anticancer Res2021 Nov 01; 41
AB  - Background/Aim: LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018. The aim of the study was to assess the stage of the disease at the time of diagnosis, percentage of morphological types, survival, percentage of driving mutations, eligibility for radical surgery, and percentage of patients who undergo radical surgery, in the non-smoking population in comparison with smokers and former smokers. Patients and Methods: The total number of patients in the registry at the time of the analysis was 2,743. Only 2,439 patients with complete records (smoking status, stage, and type of tumor) were included in this study. Results: The analysis indicated that non-smokers are diagnosed at a later stage of the disease but they have a better survival rate than smokers. Fewer smokers with stage III disease who are eligible for radical surgery will undergo surgery compared to non-smokers with the same clinical stage. Driving mutations are more common in non-smokers, even after adjustment for the more frequent occurrence of adenocarcinoma in the group of non-smokers. Conclusion: The data from LUCAS registry are consistent with already known facts, suggesting that the LUCAS registry is a useful clinical tool.